Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas

American Journal of Clinical Pathology

Volumn 113, Issue 4, 2000, Pages 512-518

  Chang, Chung Che ^a,c   Liu, Yao Chang ^b   Cleveland, Ronald P ^b   Perkins, Sherrie L ^c,d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c ARUP LABORATORIES   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

c Myc; Diffuse large B cell lymphoma; DLBCL; Expression; Outcome; p53

Indexed keywords

PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE C MYC; PRIORITY JOURNAL; SURVIVAL; TUMOR SUPPRESSOR GENE;

EID: 0034090683     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/yhfe-r65b-d3lk-3ggv     Document Type: Article

References (29)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification ot lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
2. International Lymphoma Study Group. A clinical evaluation of the international lymphoma study group classification of the non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
3. Kramer MHH, Hermans J, Wijburg E, et al. Clinical relevance ot BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
4. Offit K, Le Coco F, Louie DC, et al. Rearrangement of the BCL6 gene as a prognostic marker in diffuse large cell lymphoma. N Engl J Med. 1994;331:74-80.
5. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype and clinical outcome in 217 patients. Blood. 1994;83:2425-2427.
6. Yunis JJ, Mayer MG, Arnesen MA, et al. BCL2 and other genomic alterations in the prognosis ot large cell lymphoma. N Engl J Med. 1989;320:1047-1054.
7. Offit K, Koduru PRK, Hollis R, et al. 18q21 rearrangements in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol. 1989;72:178-183.
8. Jacobson J, Wilkes B, Kwaiatkowski D, et al. BCL2 rearrangements in de novo diffuse large cell lymphoma: association with distinctive clinical features. Cancer. 1993;72:231-236.
9. Tang SC, Visser L, Hepperle B, et al. Clinical significance of BCL2 mbr gene rearrangement and protein expression in diffuse large cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol. 1994;12:149-154.
10. Hill ME, MacLennan KA, Cunningham D, et al. Prognostic significance ot BCL2 expression and BCL2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood. 1996;88:1046-1051.
11. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance ot BCL2 protein expression and BCL2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
12. Raghoebier S, Kramer MH, van Krieken JH, et al. Essential differences in oncogene involvement between primary nodal and exrranodal large cell lymphoma. Blood. 1991;15:2680-2685.
13. Ladanyi M, Offit K, Jhanwar SC, et al. MYC rearrangement and translocation involving hand 8q24 in diffuse large cell lymphomas. Blood. 1991;77:1057-1063.
14. Vitolo U, Gaidano G, Botto B, et al. Rearrangement of bcl-6, bcl2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55-61.
15. Carbone A, Gaidano G, Gloghini A, et al. bcl-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr-virus-encoded latent membrane protein-1 expression. Am J Pathol. 1997;150:155-165.
16. The International Non-Hodgkin's lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
17. Kramer MHH, Hermans J, Parker J, et al. Clinical significance of BCL2 and p53 protein expression in diffuse large B-cell lymphoma: a population based study. J Clin Oncol. 1996;14:2131-2138.
18. Miller TP, Grogan TM, Dahlber S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460-1466.
19. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile ot primary central nervous system lymphoma identities distinct categories ot the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011-1019.
20. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 1998;92:234-240.
21. Van Krieken JH, Kluin PM. The association of c-myc rearrangements with specific types of human non-Hodgkin's lymphomas. Leuk Lymphoma. 1992;7:371-376.
22. Hermann M, Scholman HJ, Marafioti T, et al. Differential expression of apoptosis, Bcl-x and c-myc in normal and malignant lymphoid tissues. Eur J Haematol. 1997;59:20-30.
23. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
24. Le Coco F, Gaidano G, Louie DC, et al. P53 mutations are associated with histologic transformation ot follicular lymphoma. Blood. 1993;82:2289-2295.
25. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood. 1992;79:2701-2707.
26. Yano T, Jaffe ES, Longo DL, et al. MYC rearrangements in histologically progressed follicular lymphoma. Blood. 1992;80:758-767.
27. Dalla-Favera R, Ye BH, Lo Coco F, et al. Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann Oncol. 1994;5(suppl 1):55-60.
28. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of BCL2 protein expression in aggressive non-Hodgkin's lymphoma. Blood. 1996;87:265-272.
29. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998;16:1931-1939.